AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-22. (Canceled)

- 23. (Currently amended) A method for coupling a <u>an</u> oligosaccharide comprising a phosphorylated <u>hexese mannose</u> to a lysosomal enzyme, the method comprising the steps of:
- (a) derivatizing the oligosaccharide comprising a phosphorylated hexose with a compound containing to generate a carbonyl-reactive group;
- (b) oxidizing the lysosomal enzyme to generate at least one carbonyl group on the lysosomal enzyme; and
- (c) reacting the derivatized oligosaccharide with the oxidized lysosomal enzyme,

thereby coupling the oligosaccharide to the lysosomal enzyme.

- 24. (Currently amended) The method according to claim 23, wherein the phosphorylated hexase phosphate group is linked to is a terminal mannose hexase.
- 25. (Currently amended) The method according to claim 23, wherein the phosphorylated hexose phosphate group is linked to is a penultimate mannose hexose.
 - 26. (Canceled)
- 27. (Currently amended) The method according to claim 23, wherein the oligosaccharide comprises two or more M6P mannose-6-phosphate (M6P) groups.

- 28. (Previously presented) The method according to claim 23, wherein the oxidizing step is carried out with periodate or galactose oxidase.
- 29. (Currently amended) The method according to claim 23, wherein the lysosomal enzyme is deficient in a lysosomal storage disease chosen from Fabry disease, Pompe disease, Tay-Sachs disease, Hurler <u>disease</u>, er Hurler-Scheie disease, Krabbe disease, Hunter disease, <u>Mm</u>etachromatic leukodystrophy, Sanfilippo A, and <u>Sanfilippo</u> B disease, Morquip disease, Maroteaux-Lamy disease, and Gaucher disease.
- 30. (Previously presented) The method according to claim 23, wherein the lysosomal enzyme is chosen from beta-glucocerebrosidase, alpha-galactosidase A, acid alpha-glucosidase, alpha-N-acetylglucosaminidase, beta-N-acetyl-hexosaminidase, and beta-glucuronidase.
- 31. (Previously presented) The method according to claim 23, wherein the oligosaccharide is chosen from a biantennary mannopyranosyl oligosaccharide and a triantennary mannopyranosyl oligosaccharide.
- 32. (Previously presented) The method according to claim 31, wherein the biantennary mannopyranosyl oligosaccharide comprises bis-M6P.
- 33. (Previously presented). The method according to claim 31, wherein the triantennary mannopyrannosyl oligoscacharide comprises bis-M6P or tri-M6P.
- 34. (Currently amended) The method according to claim 23, wherein the oligosaccharide comprises:

6 P M (alpha 1, 2) M(alpha 1, 3)-

М

6-P M(alpha 1, 2) M(alpha 1, 6)

6-P-M(alpha 1, 2)-M(alpha 1, 3)

M
6-P-M(alpha 1, 2)-M(alpha 1, 6)

wherein M is mannose or a mannopyranosyl group.

35. (Currently amended) The method according to claim 23, wherein the derivatized oligosaccharide has a formula chosen from 6-P-M_n-R and (6-P-M_x)_mL_n-R, wherein M is mannose or a mannopyranosyl group,

P is a phosphate group linked to the C-6 position of M,

L is a hexose,

R is a compound containing has at least one carbonyl-reactive group,

m is an integer ranging from 2 to 3,

n is an integer ranging from 1 to 15, wherein if n>1, the $M_n L_n$ are linked to one another by alpha (1,2), alpha (1,3), alpha (1,4), or alpha (1, 6), and

x is an integer ranging from 1 to 15.

- 36. (Previously presented) The method according to claim 35, wherein at least one L is mannose.
- 37. (Previously presented) The method according to claim 35, wherein at least one L is chosen from galactose, N-acetylglucosamine, and fucose.
- 38. (Currently amended) The method according to claim 23 or claim 35, wherein the compound centaining at least one carbonyl-reactive group is chosen from a hydrazine, a hydrazide, an aminoexyl aminoexy, a semicarbezide semicarbazide.

- 39. (Previously presented) The method according to claim 23, further comprising the step of adding a reducing agent to the coupled lysosomal enzyme.
- 40. (Previously presented) The method according to claim 39, wherein the reducing agent comprises cyanoborohydride.
- 41. (New) The method of claim 23, wherein the lysosomal enzyme is deficient in Pompe disease and the carbonyl-reactive group is chosen from a hydrazine, a hydrazide, an aminooxy, a semicarbazide.
- 42. (New) The method of claim 23, wherein the lysosomal enzyme is acid alpha-glucosidase.
- 43. (New) The method of claim 23, wherein the carbonyl-reactive group is aminooxy.